| Bioactivity | BIM-26226, gastrin-releasing peptide, is a potent and selective antagonist of bombesin receptor. BIM-26226 inhibits BN- or GRP-stimulated amylase release with IC50s in the nanomolar range. BIM-26226 can be used for the research of cancer[1][2]. |
| Target | bombesin receptor |
| Name | BIM-26226 |
| CAS | 136207-23-3 |
| Formula | C49H63F5N12O10 |
| Molar Mass | 1075.09 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dietrich JB, et, al. Effects of BIM26226, a potent and specific bombesin receptor antagonist, on amylase release and binding of bombesin-like peptides to AR4-2J cells. Regul Pept. 1994 Oct 21;53(3):165-73. [2]. Damgé C, et, al. Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma. Eur J Pharmacol. 1998 Apr 17;347(1):77-86. |
BIM-26226
CAS: 136207-23-3 F: C49H63F5N12O10 W: 1075.09
BIM-26226, gastrin-releasing peptide, is a potent and selective antagonist of bombesin receptor. BIM-26226 inhibits BN-
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.